Overview

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir
Phase:
Phase 3
Details
Lead Sponsor:
Abbott
Treatments:
HIV Protease Inhibitors
Lopinavir
Protease Inhibitors
Reverse Transcriptase Inhibitors
Ritonavir